Program Faculty

As a physician-scientist, Wondisford’s well-funded research program focuses on pituitary and pancreatic hormonal growth and regulation. He is the inventor of the approach to synthesize recombinant human TSH, for which he holds two U.S. patents. Recombinant human TSH (Thyrogen) is FDA-approved for use in the diagnosis and treatment of patients with thyroid cancer.